Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1996-8-15
|
| pubmed:abstractText |
Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma. Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 micrograms/mouse) showed that a 0.35 micrograms dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 micrograms/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 alpha-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0262-0898
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
219-29
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8674276-Animals,
pubmed-meshheading:8674276-Antineoplastic Agents,
pubmed-meshheading:8674276-Bone Marrow Transplantation,
pubmed-meshheading:8674276-Female,
pubmed-meshheading:8674276-Hematopoiesis,
pubmed-meshheading:8674276-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:8674276-Immunophenotyping,
pubmed-meshheading:8674276-Interleukin-12,
pubmed-meshheading:8674276-Interleukin-2,
pubmed-meshheading:8674276-Liver Neoplasms, Experimental,
pubmed-meshheading:8674276-Lymphoma,
pubmed-meshheading:8674276-Lymphoma, B-Cell,
pubmed-meshheading:8674276-Mice,
pubmed-meshheading:8674276-Mice, Inbred BALB C,
pubmed-meshheading:8674276-Neoplasm, Residual,
pubmed-meshheading:8674276-Neoplasm Transplantation,
pubmed-meshheading:8674276-Organ Size,
pubmed-meshheading:8674276-Spleen,
pubmed-meshheading:8674276-Stem Cells,
pubmed-meshheading:8674276-Time Factors,
pubmed-meshheading:8674276-Tumor Cells, Cultured
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma.
|
| pubmed:affiliation |
Department of Cell Biology, University of Nebraska Medical Center, Omaha, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|